Literature DB >> 10778939

Simple and sensitive high-performance liquid chromatographic.

K Na-Bangchang1, O Supasyndh, T Supaporn, V Banmairuroi, J Karbwang.   

Abstract

A rapid, selective, sensitive, and reproducible reversed-phase HPLC procedure for the quantitative determination of mycophenolic acid (MPA)--an active plasma metabolite of the immunosuppressant mycophenolate mofetil (MMF) in plasma is described. The procedure involves one-step extraction of MPA and the internal standard, standard [RS-60461-000: (E)-6-[1,3-dihydro-4-(4-carboxy-butoxy)-6-methoxy-7-methyl-3-oxo-5-is obenzo-furanyl-4-methyl-4-hexenoic acid] with dichloromethane-dichloroethane (1:1, v/v) at acidic pH. Chromatographic separation consisted of the mobile phase [acetonitrile-0.05% phosphate buffer, pH 3.4 (45:55, v/v)] running through the column (Techopak-10 C18) at flow-rate of 0.8 ml/min. Detection was at UV wavelength of 254 nm. The mean recoveries of MPA and the internal standard at concentrations of 0.1 and 20 microg/ml were 89-98%, and 90-96%, respectively. The within-day coefficients of variation for MPA were 0.3-7.8% and the day-to-day coefficients of variation were 1.1-2.0%. The minimum detectable concentrations for both MPA and the internal standard in plasma were 0.005 microg/ml. The method was found to be suitable for use in clinical pharmacokinetic study.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10778939     DOI: 10.1016/s0378-4347(99)00487-9

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  6 in total

1.  Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients.

Authors:  Marc Labriffe; Julien Vaidie; Caroline Monchaud; Jean Debord; Pascal Turlure; Stephane Girault; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

2.  Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice.

Authors:  C A Jonsson; H Carlsten
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.

Authors:  Franck Saint-Marcoux; Bernard Royer; Jean Debord; Fabrice Larosa; Faezeh Legrand; Eric Deconinck; Jean-Pierre Kantelip; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.

Authors:  Aurelija Noreikaitė; Franck Saint-Marcoux; Pierre Marquet; Edmundas Kaduševičius; Edgaras Stankevičius
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

5.  Development and validation of HPTLC method for the determination of mycophenolate mofetil in bulk and pharmaceutical formulation.

Authors:  S Kathirvel; K Rajendra Prasad; K Madhu Babu
Journal:  Pharm Methods       Date:  2012-07

6.  Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C0 and AUC.

Authors:  Aurelija Radzevičienė; Edgaras Stankevičius; Franck Saint-Marcoux; Pierre Marquet; Rima Maslauskienë; Edmundas Kaduševičius
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.